Invest in CSL Ltd on Stash

CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.

To buy fractional shares

of CSL Ltd stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

CSL Ltd

Ticker: CSLLY

CSL Ltd

$97.66

+0.09%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years.

CSLLY Performance Breakdown

Share Price

$97.66

Today's change

1.12%

Year to date change (YTD)

-6.27%

Dividend yield

1.15

Last dividend paid

$0.52

Last dividend pay date

4/11/2022

About CSLLY

CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.

CSL Ltd Stock Ticker

CSLLY

For more information

https://www.csl.com.au

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years.

Certain companies are volatile.

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,8 recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.1

Learn how to invest

Get professional advice and education at every step.

How to buy CSL Ltd stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Stash offers three subscription plans: Stash Beginner, Stash Growth, and Stash+. Our Beginner plan starts at just $1 per month.

Once your market order of CSL Ltd stock is complete, you'll officially be a shareholder of CSL Ltd!

Invest in CSL Ltd on Stash

CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.

To buy fractional shares

of CSL Ltd stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Subscribe to The Wallet!

Looking for financial guidance? Check your Wallet. Every week, your inbox will be packed with market savviness and clever money management techniques. Sign up today!

By using this website you agree to our Terms of Use and Privacy Policy.

Ready to start
building wealth?

By using this website you agree to our Terms of Use and Privacy Policy.